Implantable Defibrillators in Long QT Syndrome, Brugada Syndrome, Hypertrophic Cardiomyopathy, and Arrhythmogenic Right Ventricular Cardiomyopathy
Authors:
- 1 May 2014
- journal article
- review article
- Published by Elsevier in Cardiology Clinics
- Vol. 32 (2) , 305-318
Abstract
No abstract availableKeywords
This publication has 105 references indexed in Scilit:
- Incidence and Predictors of Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Undergoing Implantable Cardioverter-Defibrillator Implantation for Primary PreventionJACC, 2011
- Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approachEuropean Heart Journal, 2010
- Defibrillation Threshold Testing in Patients with Hypertrophic CardiomyopathyPacing and Clinical Electrophysiology, 2010
- Recent progress in congenital long QT syndromeCurrent Opinion in Cardiology, 2010
- Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/DysplasiaCirculation, 2010
- The acquired Brugada syndrome and the paradox of choiceHeart Rhythm, 2009
- Efficacy of Antiarrhythmic Drugs in Arrhythmogenic Right Ventricular CardiomyopathyJACC, 2009
- Importance of Knowing the Genotype and the Specific Mutation When Managing Patients With Long-QT SyndromeCirculation: Arrhythmia and Electrophysiology, 2008
- Risk of death in the long QT syndrome when a sibling has diedHeart Rhythm, 2008
- Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathyHeart, 2007